SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
149.80    -16.00 (-9.65%)
Bid:
149.20
Ask:
150.20
Spread: 1.00 (0.67%)
Market Cap: £255.95m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Trading and Acquisition Update

Today 07:00

RNS Number : 0212I
McBride PLC
12 June 2026
 

12 June 2026

McBride plc

 

Trading and Acquisition Update

 

McBride plc ("McBride" or the "Group"), the leading European manufacturer and supplier of private label and contract manufactured products for the domestic household and professional cleaning/hygiene markets, today provides an update on current trading conditions and progress on the proposed acquisition of Eurotop SAS, owner of the Eurotab Group ("Eurotab").

 

Trading update

 

In our trading conditions statement issued on 2 April 2026, we noted the potential impact of the Middle East crisis on raw material, packaging and haulage input costs. Since April, we have experienced sustained cost increases in petrochemical-derived and energy-intensive materials as a consequence of the current Middle East conflict.

 

Our price recovery actions, tied to our 3-month pricing approach, have progressed through the past weeks, working closely with our customers to secure offsetting price increases. The cumulative impact on input costs has exceeded our original expectations due to the continuing and prolonged period of the conflict, which has required a second phase of price recovery actions.

 

Whilst the duration of this conflict remains uncertain, at this stage we are of the view that direct cost pressures are unlikely to either rise considerably further or experience meaningful near-term decline.

 

Due to the standard time lag between rising input costs and price implementation, we expect the financial impact to be concentrated within our Q4 FY26 and Q1 FY27 results. We anticipate limiting this total exposure to less than a full 3-month cost impact. We expect performance to normalise and to be back on track with previous expectations for FY27 heading into Q2 FY27 and beyond. Therefore, the Group now expects FY26 and FY27 adjusted EBITA to be between 5 and 10% lower than current analysts' expectations*.

 

As stated in our April update, the Group notes that following previous periods of rapid inflation, there has been resilient and growing demand for private label cleaning products because of the compelling value for money proposition for consumers as rising general inflation leads to affordability challenges.

 

Eurotab acquisition

 

The Group is pleased to announce it expects to complete the acquisition of Eurotab on or around 1 July 2026. This acquisition represents an attractive strategic opportunity and is expected to further reinforce the strong market position of McBride's Unit Dosing division in the European detergent market and bring meaningful scale to the Group. A further announcement to confirm the completion will be made in early July.

 

*Analysts' expectations refer to a Group-compiled consensus for adjusted EBITA for the year ending 30 June 2026 of £64.2m and for the year 30 June 2027 of £70.6m

 

For further information, please contact:

 

McBride plc

Via TEAM LEWIS

Chris Smith, Chief Executive Officer

Mark Strickland, Chief Financial Officer

TEAM LEWIS

McBride@teamlewis.com

Hannah Scott

+44 (0)20 7802 2634

Galyna Kulachek

+44 (0)20 7802 2617

 

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016. The person responsible for arranging the release of this announcement on behalf of McBride is Rob Henry, General Counsel and Company Secretary.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAVKRNOUNAAR
Date   Source Headline
12th Jun 20267:00 amRNSTrading and Acquisition Update
11th Jun 20261:44 pmRNSDirector/PDMR Shareholding
2nd Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSTransaction in Own Shares
19th May 20267:00 amRNSTransaction in Own Shares
12th May 20267:00 amRNSTransaction in Own Shares
6th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSSecond tranche of share buyback programme
1st May 20267:00 amRNSTransaction in Own Shares
29th Apr 20267:00 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSTransaction in Own Shares
15th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSTransaction in Own Shares
2nd Apr 20267:00 amRNSProposed Acquisition & Trading Conditions Update
1st Apr 20267:00 amRNSTransaction in Own Shares
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20267:00 amRNSTransaction in Own Shares
27th Mar 20267:00 amRNSTransaction in Own Shares
26th Mar 20267:00 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
24th Mar 20267:00 amRNSTransaction in Own Shares
23rd Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 20267:00 amRNSTransaction in Own Shares
19th Mar 20267:00 amRNSTransaction in Own Shares
18th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
17th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
16th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
13th Mar 20267:00 amRNSTransaction in Own Shares
12th Mar 20267:00 amRNSTransaction in Own Shares
11th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSDirector Appointment
10th Mar 20267:00 amRNSTransaction in Own Shares
10th Mar 20267:00 amRNSTransaction in Own Shares
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20266:28 pmRNSDirectorate change
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:05 amRNSInterim results for 6M ended 31 December 2025

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.